Pneumococcal hemolytic uremic syndrome (HUS) in children is caused by infections with Streptococcus pneumoniae. Because endothelial cell damage is a hallmark of HUS, we studied how HUS-inducing pneumococci derived from infant HUS patients during the acute phase disrupt the endothelial layer. HUS pneumococci efficiently bound human plasminogen. These clinical isolates of HUS pneumococci efficiently bound human plasminogen via the bacterial surface proteins Tuf and PspC. When activated to plasmin at the bacterial surface, the active protease degraded fibrinogen and cleaved C3b. Here, we show that PspC is a pneumococcal plasminogen receptor and that plasmin generated on the surface of HUS pneumococci damages endothelial cells, causing endothelial retraction and exposure of the underlying matrix. Thus, HUS pneumococci damage endothelial cells in the blood vessels and disturb local complement homeostasis. Thereby, HUS pneumococci promote a thrombogenic state that drives HUS pathology.
Hemolytic uremic syndrome (HUS) is defined by acute hemolytic anemia, thrombocytopenia, and acute kidney injury. The disease has several causes, including infection with Streptococcus pneumoniae or Shiga toxin-producing Escherichia coli, (STEC-HUS), as well as a genetic or autoimmune etiology. Genetic HUS, also called aHUS, and the autoimmune form DEAP-HUS, are associated with defective complement regulation, which results in endothelial cell damage, cell retraction, and subsequent exposure of the subendothelial matrix [1, 2] .
STEC-HUS accounts for the majority of HUS cases, whereas genetic HUS, which occurs mostly in adults, is a polygenic disease. Genetic changes such as mutations, copy number variations, and deletions or insertions affect several human complement genes, including Factor H, CFHR1, CFHR3, C3, Factor B, MCP/ CD46, Factor I, and thrombomodulin [3] [4] [5] [6] [7] [8] . In addition, mutations in the diacyl-glycerol-kinase (DGKε) gene are associated with aHUS. DGKε, by mediating cytoplasmic signaling, regulates the response of endothelial cells to complement stress [9] . Additional secondary triggering factors such as infections and pregnancy can induce the disease. DEAP-HUS describes the autoimmune form, deficient for CFHR11 and CFHR3 genes and autoantibody-positive form of HUS. The majority of autoimmune patients with develop autoantibodies, which bind to the C-terminal recognition region of Factor and have a homozygous genetic deficiency of CFHR1 and CFHR3 genes [2, 6] . DEAP-HUS accounts for 13%-15% of noninfectious HUS cases and is most often caused by autoantigens that bind to the C-terminal recognition region of Factor H [8, [10] [11] [12] [13] ; most DEAP-HUS patients have a homozygous CFHR1-CFHR3 deficiency [6, 8] .
The majority of pneumococcal HUS patients present with pneumonia. Pneumococcal HUS accounts for 5%-15% of HUS cases, but appears to be underdiagnosed [14, 15] . The pathogenesis of pneumococcal HUS is largely unknown. Neuraminidase released by pneumococci is thought to damage endothelial cells, leading to cell retraction and exposure of the subendothelial matrix of and the Thomsen-Friedenreich antigen. This specific self-antigen may initiate complement activation and coagulation, ultimately leading to endothelial injury and hemolysis [14, 15] .
Binding of human plasminogen to pneumococci blocks complement activation at the bacterial surface and subsequently inhibits the formation of effector molecules [16, 17] . Streptococcus pneumoniae utilizes several surface proteins to acquire plasminogen from host plasma, that is, translation elongation factor Tu (Tuf) [18] , α-enolase [19] , glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [20] , choline-binding protein E [21] , endopeptidase [22] , and phosphoglycerate kinase [23] .
In addition, 2 S. pneumoniae Factor H-binding proteins are identified: Tuf [20] and pneumococcal surface protein C (PspC) [16, 17, [24] [25] [26] [27] [28] . Tuf is a moonlighting protein and is present at many locations [18, 29, 30] . PspC, which is also known as CbpA, SpsA, or Hic, is a major pneumococcal surface protein [31, 32] . PspC genes are expressed by many virulence strains and encode a family of polymorphic immune evasion proteins. Based on the type of membrane anchor, PspC family proteins are split into 2 subgroups. Subgroup I proteins harbor conserved C-terminal choline-binding domains (Chd), which integrate into the bacterial membrane. The 6 subtypes, 1-6, differ according to the number of Chb segments, which range from 7 to 13 [33, 34] . The Chb anchoring region is followed by a conserved 18 amino acid C-terminal stretch [32] . Members of subgroup II-that is, nonclassical or PspC-like proteins (subtypes 7-11)-expose a conserved C-terminal LPxTG-motif, that is cleaved by the transpeptidase sortase A and is covalently linked to bacterial peptidoglycan [33, 35] .
Here, we examined how 2 pneumococcal strains isolated from infant HUS patients cause HUS pathology. Both clinical HUS isolates efficiently bound plasminogen. The HUS pneumococci expressed a new and a rare variant of PspC subgroup I, and we identify PspC as a novel pneumococcal plasminogen receptor. Plasminogen attached to the clinical PspC variants as well as to the clinical HUS strains was converted to plasmin, which damaged endothelial cells via activated plasmin. These results provide new insight into the mechanisms underlying the pathology of pneumococcal HUS. HUS pneumococci efficiently acquire human plasminogen, which when activated under immune stress, mediates endothelial cell damage resulting in cell retraction and exposure of the subendothelial matrix.
MATERIALS AND METHODS

Bacterial Isolates and Cultivation
Two S. pneumoniae strains were isolated from 5-year-old (#1863) and 2-year-old (#2194) female patients with HUS. Both clinical isolates (Sp HUS A and Sp HUS B), S. pneumoniae D39 (NCTC 7466, serotype 2), and the D39 pspC ko-strain were cultivated on blood agar plates [18] . The study was approved by the ethical committee of the Medical Faculty of the FriedrichSchiller-University (Jena, Germany).
Enzyme-Linked Immunosorbent Assay
Binding of purified plasminogen (Technoclone GmbH, Vienna, Austria) and of serum-derived plasminogen to intact pneumococci and to proteins PspC6, PspC3, and PspC2.1-SH2 was evaluated as described previously [36] . Bound Factor H or plasminogen was detected with monoclonal antibody (mAb) T13 [37] or mAb GTX79688 (GeneTex Inc, Irvine, California).
Flow Cytometry
Plasminogen (50 µg/mL in Dulbecco's Phosphate-Baffered Saline [DPBS]) was bound to CellTraceCalcein-Violet-labeled HUS pneumococci (2 × 10 8 ) for 1 hour at 37°C. Bacteria were pelleted and washed. Bound Factor H was detected with mAb T13 by flow cytometry (LSR II, BD, Franklin Lakes, New Jersey). Median fluorescence of 10 000 intact pneumococci was evaluated (FlowJo software version 7.2.5).
Fluorescence Microscopy
Purified plasminogen (50 µg/mL) as well as serum-derived plasminogen (heat inactivated normal human serum [iNHS] 50%) bound to pneumococci (2 × 10 8 ), was detected with mAb GTX79688, and bacterial DNA was stained with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, Taufkirchen, Germany). Pneumococci were transferred to a glass slide, dried and fixed, and evaluated by confocal microscopy (LSM 710, Carl Zeiss AG, Oberkochen, Germany).
PspC Expression
PspC expression on the pneumococcal surface was evaluated with polyclonal PspC antiserum as reported elsewhere [18] . Membrane proteins were prepared from pneumococci (Sp HUS A, Sp HUS B, D39, and D39ΔpspC) cultivated overnight. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a membrane (GE Healthcare, Freiburg, Germany). PspC was identified with a rabbit antiserum together with HRP-coupled goat anti rabbit serum (Dako, Hamburg, Germany). After washing, chemiluminescence was recorded (Fusion-FX7, Vilber Lourmat, Eberhardzell, Germany).
Amplification of the pspC Genes
Genomic DNA was isolated from the clinical HUS pneumococci Sp HUS A and Sp HUS B, D39, and the D39 pspC knockout strain (GenElute Bacterial genomic DNA Kit; Sigma-Aldrich, Taufkirchen, Germany). The pspC genes were amplified with primers PspC_2R_F07_fwd-GGATCCTTGTTTGCATCAAAAAGCGAAAG and PspC_ 2R_F08_rev-AAGCTTGTTTAGTTTACCCATTCACCATTG in 35 polymerase chain reaction (PCR) cycles using Phusion High-Fidelity DNA Polymerase (New England Biolabs GmbH, Frankfurt am Main, Germany). The amplicons were separated by gel electrophoresis and sequenced (3130×/Genetic Analyzer, Thermo Fisher Scientific GmbH, Dreieich, Germany). The DNA sequences were deposited in GenBank BankIt1954320 SPHUSA-PspC; KX874547 and BankIt1954320 SPHUSB-PspC; KX874548.
Cloning and Expression of PspC6 and PspC3
The pspC genes of HUS isolates Sp HUS A and Sp HUS B were amplified by PCR using conserved primers CM11_fwd CACCATGTTTGCATCAAAAAGCG and CM10_rev TTAGTTTACCCATTCACCATTGGC. After ligation into a pET 200/D-TOPO vector, plasmids were transformed into Escherichia coli. Bacteria were grown in presence of kanamycin (50 µg/mL) overnight. Plasmids were isolated and then transformed into E. coli (BL-21 Star. Protein expression and purification were performed as described recently [38] . In brief, IPTG (1 mM) was added; after 4 hours bacteria were harvested, lysed, and sonicated on ice. Inclusion bodies were solubilized in dispersion buffer (100 mM Tris, pH 8.0, 50 mM glycine, 8 M urea, 5 mM l-glutathione reduced, 0.5 mM l-glutathione oxidized). Recombinant His-tagged PspC was purified by affinity chromatography as described [38] .
BioLayer Interferometry
Plasminogen binding of to PspC6, PspC3, or PspC2.1-SH2 was analyzed by biolayer interferometry using a single channel BLItz system (Forte Bio, Menlo Park, California). Recombinant PspC was loaded to an nickel-charged nitrilotriacetic acid (Ni-NTA)-biosensor, and plasminogen was added as analyte at concentrations of 50, 500, 1000, 2500, or 5000 nM. Complex formation was followed for 240 seconds, then DPBS was added and the dissociation was followed. Binding was normalized by adjusting to a buffer control and K D values were determined with BLItzPro software [39] .
Generation of Plasmin and Analysis of Plasmin-Mediated Substrate
Degradation
Plasminogen (10 µg/mL) was bound to immobilized PspC6, PspC3, or Tuf (60 nM) or to intact pneumococci (2 × 10 8 ). After addition of uPA (1 µg/mL), cleavage of the chromogenic substrate S2251, fibrinogen (1 µg/mL), or C3b (10 µg/mL) was evaluated as described previously [40] .
Cell Viability
HUVECs (ATCC CRL-1730) were cultivated in DMEM. Cells grown to confluence were challenged with plasminogen, or with plasminogen attached to pneumococci (3 × 10 6 ) together with tPA for 24 hours. Following washing, CellTiter-blue (Promega GmbH, Mannheim, Germany) was added and resorufin generation was followed. Retraction of HUVECs from their surface upon exposure with plasminogen-coated pneumococci (5 × 10 7 ) in presence of tPA was evaluated by confocal microscopy after 1 hour. Following washing, the cells were fixed, stained with DAPI and wheat-germ agglutinin Texas Red (TR) (Thermo Fisher Scientific).
Quantification of the Retraction of Endothelial Cells
The number of holes and the extent of cell damage were quantified using confocal images of TR-and of DAPI-labeled cells. For image analysis, a custom-written macro in the Fiji distribution of ImageJ (version 1.51f) was applied. First, TR-image was thresholded at 5%-7% based on the individual image histogram. The thresholded image was then converted into a binary image (mask), which was then blurred by a Gaussian kernel of 11 pixel width. These converted images were inverted, thresholded according to the Otsu algorithm, and transferred to a binary mask. Any holes in the mask were filled and then the mask was eroded by 10 pixels. False-positive holes in the eroded mask were corrected by the DAPI image as refinement tool by following the same procedure. The corrected mask was analyzed with a particle finder algorithm that identified holes in a predefined size and shape range. The minimum size of the holes was based on the average cell size, and the upper limit of the hole size was set to the total image area, allowing the identification of large holes. This workflow with the same parameter settings was used for all images, avoiding any bias in the image analysis.
For statistical analyses, the unpaired t test was used and significance is indicated.
RESULTS
Clinical Isolates of HUS Pneumococci Efficiently Bind Human Plasminogen
First, binding of human plasminogen to the clinical HUS isolates was studied. Both HUS isolates bound twice as much plasminogen as the virulent reference strain D39 as shown by enzyme-linked immunosorbent assay (ELISA) and flow cytometry ( Figure 1A 
Plasminogen Bound to HUS Pneumococci Is Converted to Plasmin
To analyze if plasminogen attached to the surface of the clinical HUS isolates can be activated and may contribute to pneumococcal immune evasion, first plasminogen which was bound to the clinical HUS isolates was activated by uPA. Active plasmin cleaved the chromogenic substrate S-2251 in a time-dependent manner ( Figure 2A ). Plasminogen attached to Sp HUS A or Sp HUS B was about 1.7-and 1.4-fold more effective, than plasminogen attached to D39. Also, plasminogen attached to the HUS pneumococci and activated by uPA cleaved the extracellular-matrix protein fibrinogen, as evidenced by the disappearance of the 76-, 72-, and 50-kDa bands ( Figure 2B ). Similarly, surface-attached active plasmin cleaved C3b, as shown by the appearance of the cleavage fragments αʹ68, αʹ45, and αʹ38 ( Figure 2C ).
The 2 Clinical HUS Pneumococcal Strains Express a Rare and a New PspC Variant
To characterize immune evasion proteins of Hus pneumococci, expression of Tuf and PspC was analyzed. Tuf was expressed at higher levels at the bacterial surface (data not shown). Both clinical isolates expressed twice as much PspC on their surface than D39 and the D39 pspC-ko strain as shown by ELISA ( Figure 3A ) and by flow cytometry (Sp HUS A: ΔMFI: 6957; Sp HUS B: ΔMFI: 7535; D39 ΔMFI: 1036; and pspC-ko ΔMFI: 32) ( Figure 3B ). The PspC proteins expressed on the outer membrane of each strain showed different mobilities and appeared as 105-kDa (PspC-Sp HUS A), 85-kDa (PspC-Sp HUS B), and 98-kDa bands (PspC3.1-D39) ( Figure 3C) . Similarly, the corresponding PspC genes differed in length: Sp HUS A, 2.2-kbp, Sp HUS B, 1.9 kbp, and D39 (pspC3.1) 2.0 kbp ( Figure 3D ). The PspC genes expressed by both clinical isolates were sequenced. The encoded proteins of 735 (PspC6) and 644 (PspC3) amino acid residues showed an overall sequence homology of 69.9%. Both variants had the typical domain organization of PspC, but differed in terms of the C-terminal choline-binding repeats ( Figure 4A) . A protein database search (BLASTP 2.5.0, 15 January 2017) revealed that PspCSp HUS A showed a 100% match with entry WP_000458099.1. However, PspC-Sp HUS B did not fully match any genes in the database, although it did show 96% homology to entries WP_061846540.1 and WP_061832273.1, 83.6% homology to PspC3_13, and 80.5% homology to PspC3_9. Thus, HUS isolate Sp HUS A expresses a rare PspC variant within subtype 6, and Sp HUS B is a new variant within subtype 3. The sequences of 2 additional PspC genes derived from very recently obtained clinical S. pneumoniae strains from young HUS patients also show novel amino acid sequences, which, however, are related to that of the HUS strains Sp-HUS-A and Sp-HUS-B (Supplementary Figure 4) . A, Streptococcus pneumoniae isolates from patients with hemolytic uremic syndrome (HUS) bind plasminogen. The HUS pneumococcal isolates, the reference strain D39, the isogenic D39ΔpspC strain, or bovine serum albumin (BSA) were immobilized onto the surface of a microtiter plate. Plasminogen was added; after washing, bound plasminogen was detected with mouse plasminogen monoclonal antibody (mAb). Pneumococci treated with antibodies in the absence of plasminogen are termed antibody control. The mean value and standard deviation of 4 separate, independent experiments are shown and significance is indicated. *P ≤ .05; ***P ≤ .001. B, Binding of plasminogen was evaluated by flow cytometry. Plasminogen was bound to the surface of the 2 clinical isolates, D39 and the D39 pspC knockout strain. After washing, surface-bound plasminogen was detected with mouse plasminogen mAb. Pneumococci treated with antibodies in the absence of plasminogen are termed control and are shown by dashed lines. A representative experiment of 4 separate and independent experiments is shown. C, Plasminogen surface distribution on clinical HUS isolates. The clinical HUS isolate Sp HUS A was incubated with heat inactivated normal human serum (iNHS). Following washing, bound plasminogen was detected with mouse plasminogen mAb. Bacterial DNA was stained with 4′,6-diamidino-2-phenylindole (DAPI). Pneumococci were fixed on the cover slides and fluorescence was evaluated by laser microscopy. Similarly, plasminogen surface distribution was evaluated for Sp HUS B, D39, and the D39 pspC knockout strain. A representative experiment of 3 separate and independent experiments is shown.
Recombinant Expression of the PspC Variants
Next, the new and the rarely identified PspC variants encoded by the 2 clinical pneumococcal strains were cloned and the proteins were expressed. Both purified, recombinant PspC proteins were then detected by silver staining and by Western blotting as 105-kDa and 110-kDa bands (Figure 4B-D) .
PspC Is a Plasminogen Receptor and Plasminogen Bound to PspC Is
Converted to Plasmin
Because the pspC-ko bound plasminogen with a lower intensity than the parental strain ( Figure 1A and 1B) , we hypothesized that PspC binds plasminogen. Indeed, when analyzed by ELISA we found that plasminogen bound to PspC6, PspC3, and PspC2.1-SH2 (data not shown). Similarly, plasminogen bound to biosensor-attached PspC6 and PspC3, reaching saturation after 50 seconds ( Figure 5A and 5B). Plasminogen bound to PspC6 and PspC3 with similar association and dissociation rates (Supplementary Table 1 ). The affinity of plasminogen for PspC6 was 568 nM, that for PspC3 was 489 nM, and that for PspC2.1-SH2 was 1360 nM (Supplementary Figure 5) .
Treatment of PspC6-or PspC3-bound plasminogen by uPA led to cleavage of the plasmin substrate S2251 ( Figure 5C ). The proteolytic activity of plasmin attached to PspC6, PspC3, or Tuf was comparable. Activation of plasminogen bound to PspC6 or PspC3 also resulted in cleavage of fibrinogen, as evidenced by the disappearance of 76-, 72-, and 50-kDa bands, and by the appearance of degradation products (ie, bands at 45 and 40 kDa) ( Figure 5D ). In addition, plasminogen bound to the PspC variants cleaved C3b upon activation by uPA, as demonstrated by the appearance of the αʹ68, αʹ45, αʹ38, and αʹ17 fragments (data not shown).
Plasmin Damages Human Endothelial Cells
Endothelial cell damage is a hallmark of HUS. Therefore, we next asked whether plasmin, the active protease, influences endothelial metabolism and cellular integrity. Indeed, the results of an lactate dehydrogenase (LDH) assay showed that active plasmin damaged HUVECs and the metabolic activity fell by about 80% ( Figure 6A , column 2). This cell damage was prevented by the serine protease inhibitor aprotinin (column 3). Next, we asked whether active plasmin when attached to the pneumococcal surface does also have the capacity to damage HUVECs. Plasminogen bound to both HUS pneumococci and when subsequently activated by tPA reduced the metabolic activity of HUVECs by about 20% ( Figure 6B , columns 2 and 3). Again, aprotinin reversed the effect of plasmin on the cellular metabolic rate for both clinical HUS isolates (Figure 6B, columns 4 and 5). Electron microscopy showed that plasmin-mediated cellular damage disturbed cell integrity ( Figure  6C ) and caused cell retraction, resulting in subendothelial matrix exposure ( Figure 6D) . Cell retraction was then followed by confocal microscopy. Active plasmin at the surface of HUS pneumococci caused cell retraction, leading to exposure of the subendothelial matrix ( Figure 7A , upper panels). This effect was blocked by aprotinin ( Figure 7A , middle panels). By optical evaluation, it appeared that the exposed surface was larger when HUVECs were challenged with the clinical HUS pneumococci as with D39 or D39ΔpspC ( Figure 7A , upper panels). To evaluate cell retraction in a quantitative, unbiased manner, a new image analysis algorithm was established to determine the total area of the newly exposed surface matrix and the number of spots formed for a given area, and to quantitate both the total area and the mean area per spot ( Figure 7B ).
The total exposed matrix and also the mean area per spot was larger and more spots were formed when the human endothelial cells were challenged by HUS pneumococci as when in contact with the virulent D39 strain (Figure 7C and 7D ; data not shown). Thus, plasmin generated on the surface of HUS pneumococci damages endothelial cells and induces metabolic as well as morphological changes leading to cell retraction and detachment from the underlying matrix. Here, we identified a new pathologic mechanism underlying the pathogenesis of HUS. S. pneumoniae from HUS patients' bound plasminogen, resulting in damage to endothelial cells and exposure of the underlying matrix. This would then lead to thrombosis, another hallmark of HUS. Two pneumococcal isolates derived from infants with HUS efficiently bound human plasminogen very efficiently. Plasminogen was efficiently recruited to HUS pneumococci, and when activated to yield plasmin caused damage to endothelial cells, resulting in cell rounding and retraction from the underlying matrix. These data reveal a new mechanism by which HUS pneumococci induce pathogenicity: The bacteria hijack the protective host regulator, resulting in damage to the endothelium. HUS is triggered by infectious agents such as S. pneumoniae or STEC, or caused by genetic and autoimmune factors [15, 41] . Endothelial cell damage is a hallmark for HUS, which presents with related or identical pathologies regardless of the trigger. Endothelial cells lining the blood vessels of the kidney 42, are damaged and the subendothelial matrix is exposed, resulting in thrombosis and kidney failure [43, 44] . . Plasminogen bound to PspC is converted to active plasmin that cleaves chromogenic and natural substrates. A, Binding of plasminogen to PspC6 was analyzed by biolayer interferometry. PspC6 was attached to the nitrilotriacetic acid (NTA) sensor, and plasminogen was added as analyte at the indicated concentrations (50, 500, 1000, 2500, and 5000 nM). Association and complex formation was followed for 240 s and after buffer exchange, dissociation of the complexes was evaluated for the same time.
The values were normalized to the buffer control and the affinity was determined. B, Similarly, binding and the affinity of plasminogen to sensor-bound PspC3 was evaluated. C, Plasminogen bound to PspC is accessible for the urokinase plasminogen activator (uPA) and converted to the active protease plasmin. PspC6, PspC3, Tuf, plasminogen, or gelatin was attached to the surface of a microtiter plate. After blocking, plasminogen was added; then uPA and the chromogenic substrate were added. Substrate conversion was followed for 24 h. D, Plasminogen was attached to immobilized PspC6 (left panel) or PspC3 (right panel), as well as bovine serum albumin (BSA) (lane 8) or was attached directly to the surface of a microtiter plate (lane 9); then uPA and fibrinogen were added. Following incubation, the reaction mixtures were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a membrane, and fibrinogen cleavage was visualized by rabbit fibrinogen antiserum. Fibrinogen was separated directly (lane 1). Degradation of fibrinogen was evaluated after 1, 2, 4, 6, 18, and 24 h. Results from a representative experiment out of 3 separate and independent experiments are shown.
The pathogenesis of pneumococcal HUS is not completely understood, although neuraminidase-induced endothelial cell damage is thought to be relevant. Therefore, to better understand the pathology underlying pneumococcal HUS, we studied 2 clinical pneumococcal strains, both of which were isolated from infants during the acute phase of HUS. We found that both HUS pneumococci efficiently recruited plasminogen.
Here, we identified PspC, the polymorphic pneumococcal surface protein, as a new ligand for plasminogen. PspC . HUVECs cultivated to confluence in a 96-well plate were challenged with plasminogen activated by tissue plasminogen activator (tPA) for 24 h. Then cells were washed and CellTiterblue was added for 2.5 h. Reduction of resorufin turnover is a marker for cell damage as intact, living cells convert the colorimetric dye resazurin to resorufin, which is followed spectroscopically. Resorufin conversion of intact, untreated HUVECs was set to 100%. The inhibitor aprotinin (A) blocked plasmin-mediated cell damage. HUVECs lysed by Trition X100 (T) lacked metabolic activity. The mean value and standard deviation of 5 separate, independent experiments are shown and significance is indicated. ***P ≤ .001. B, Plasminogen bound to the hemolytic uremic syndrome (HUS) pneumococci damages HUVECs. Plasminogen was bound to HUS pneumococci, Sp HUS A or Sp HUS B, and activated by tPA. Then the pneumococci were added to confluent HUVECs. After 24 h, cells were washed, CellTiter-blue was added for 2.5 h, and resorufin formation was followed. Aprotinin blocked the effect of plasmin at the pneumococcal surface. The mean values and standard deviation of 4 separate, independent experiments are shown and significance is indicated. *P ≤ .05. C, Morphological changes of HUVECs upon plasmin challenge visualized by electron microscopy. Left panel: Intact HUVEC attached onto the surface form a continuous cell layer and cover almost the complete surface. Right panel: HUVECs upon plasmin challenge round up and detach from their matrix. Images are shown with 1000-and 3000-fold magnification. D, HUVECs challenged with plasmin-coated HUS pneumococci, Sp HUS A, were evaluated by electron microscopy. HUVECs are damaged by Sp HUS A; cell damage was stronger when plasmin is formed on the surface of this clinical HUS strains. Again the effect is blocked by aprotinin. Images are shown with 1000-fold magnification. . Pneumococci were then added to confluent HUVECs. After 1 h of coincubation, HUVECs were fixed, and stained with 4′,6-diamidin-2-phenylindole (DAPI) (blue) and wheat-germ agglutinin Texas Red (red). Morphology and retraction form the matrix was followed by confocal microscopy. Aprotinin was used to inhibit plasmin activity.
Results from a representative experiment of 3 separate and independent experiments are shown. B, Quantitating the total area of surface spots generated by plasmin-coated pneumococci. A bioinformatics approach was used to quantitate cell retraction by determining the cell-free area formed upon challenge with plasmin-coated pneumococci.
Yellow lines indicate the borders of the segmented holes. A representative example is depicted in this image. C, Total area of surface spots generated by plasmin-coated pneumococci. HUVECs were challenged with HUS pneumococci that had plasmin on their surface. The total area per evaluated field was determined. Multiple images as shown in (A) were evaluated by the new bioinformatics approach (B). The exposed surface is given in pixels (px). The total area of exposed spots formed upon HUVECs retraction is presented. Aprotinin blocked plasmin action. The mean value and standard deviation of 10 samples from 3 separate, independent experiments are shown and significance is indicated. ***P ≤ .001. D, Number of surface spots generated by plasmin-coated pneumococci. Multiple images (10 per condition and strain) were evaluated with the new bioinformatics approach, and the number of spots formed was determined. Aprotinin blocked HUVEC retraction and surface exposure.
bound to plasminogen on the pneumococcal surface and, when converted to plasmin, damaged HUVECs and induced cell retraction from the matrix. Both HUS pneumococcal isolates recruited about twice as much plasminogen than the highly virulent strain D39, which is used as model organism for pneumococcal pathogenesis [45] . HUS strain Sp HUS A expressed more Tuf on the surface than strains Sp HUS B and D39. Both clinical strains of HUS pneumococci and strain D39 harbored identical Tuf genes and expressed the same 55-kDa Tuf protein. HUS pneumococci expressed 3 times more PspC on the cell surface than D39. The clinical isolate Sp HUS A expressed a rare variant of PspC6, whereas Sp HUS B expressed a novel 735 amino acid variant of PspC3, which lacks 33 residues within the conserved proline-rich region.
In conclusion, HUS pneumococci isolated from infant HUS patients increase immune fitness by multiple strategies: (i) they express high levels of Tuf-and PspC; (ii) they bind high levels of human plasminogen; and (iii) they exploit plasmin to damage endothelial cells, inducing cell retraction from the surface, and exposure of the underlying extracellular matrix.
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